| Company | Value | Change | %Change |
|---|
The pharmaceutical company’s revenue grew by 13.1% on-year to ₹122.8 crore, up from ₹108.6 crore in Q3 FY24, driven by steady demand for its active pharmaceutical ingredients (APIs) and bulk drugs.
EBITDA stood at ₹21.7 crore, reflecting a 10.7% increase from ₹19.6 crore in the year-ago quarter. Meanwhile, EBITDA margin came in at 17.7%, slightly lower than 18.1% in the previous year.
Despite the strong earnings recovery, shares of Bajaj Healthcare Ltd ended the trading session down 4.47% at ₹595.60 on the BSE, ahead of the results announcement.Also read: Berger Paints Q3 Results: Profit, EBITDA gorwth flat; revenue rises over 3%
The company, which exports APIs to over 50 countries, caters to the pharmaceutical, nutraceutical, and food industries globally. It continues to expand its portfolio of speciality APIs and finished dosage formulations to drive future growth.
